Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

Abroad (travel likely)RecruitingPHASE1

Conditions

Neuroblastoma · Sarcoma · Osteosarcoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Stanford University, Palo Alto, California, United States
Contact: Study coordinator (Amy Li) · solidtumorcart@stanfordchildrens.org · 650-497-8953
Contact: Principal Investigator (Sneha Ramakrishna, MD)

Study leads

Sneha Ramakrishna, MD
Principal Investigator
Stanford University

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma

Neuroblastoma · Refractory Neuroblastoma · Relapsed Neuroblastoma

Abroad (travel likely)RecruitingPHASE1

Atlanta, United States

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Atypical Teratoid/Rhabdoid Tumor · Embryonal Tumor With Multilayered Rosettes · Ewing Sarcoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Little Rock, United States

Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Neuroblastoma · Rhabdomyosarcoma · Synovial Sarcoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Gainesville, United States

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Colorectal Carcinoma · Endometrial Carcinoma · Melanoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Birmingham, United States · Los Angeles, United States